Author + information
- Tomo Ando,
- Emmanuel Akintoye,
- Tesfaye Telila,
- Alexandros Briasoulis,
- Hisato Takagi,
- David Slovut,
- Theodore Schreiber,
- Cindy Grines and
- Luis Afonso
Background: We aimed to assess and compare the outcomes of TAVR versus SAVR in DM patients using the nationwide inpatient sample (NIS) database.
Methods: We identified diabetic patients who underwent TAVR and SAVR in DM cohorts from the nationwide inpatient sample (NIS) database through 2011 to 2013. A complete case analysis was performed for the multivariate analysis and excluded cases with missing data. The primary endpoint was in-patient all-cause mortality and secondary outcomes were perioperative complications.
Results: Our query resulted in total of 14,541(1,151 TAVR and 13,390 SAVR) aortic valve replacement. TAVR patients were older (80±8.1 years vs 70±10, p<0.001), more female (45% vs 38%, p<0.001) and predominantly white race. The primary outcome was observed less in TAVR (2.8% vs 3.6%). The rates of hemorrhage requiring transfusion (13% vs 20%), cardiac complications (6.1% vs 14%, p<0.001), respiratory complications (1.2% vs 3.7%), acute myocardial infarction (2.5% vs 2.9%, p<0.001), acute kidney injury (18% vs 19%), and sepsis (1.7% vs 3.6%) were significantly lower in TAVR compared to SAVR patients. The mean hospitalization cost was lower for TAVR than SAVR ($58,878 vs $6,3869, p=0.003). Lengths of stay (median 6 days vs 8 days, p < 0.001) were shorter in TAVR patients
Conclusions: TAVR may result in better clinical outcomes, shorter hospital stay and lower hospital cost than SAVR in DM patients.
Poster Hall, Hall C
Saturday, March 18, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Interventional Cardiology: TAVR 3
Abstract Category: 17. Interventional Cardiology: Aortic Valve Disease
Presentation Number: 1243-193
- 2017 American College of Cardiology Foundation